Cortechs.ai | Understanding Change Data in LesionQuant 2.3

Understanding Change Data in LesionQuant 2.3

Did you know that the LesionQuant module offers lesion and brain structure change data for review?

Lesion and brain structure change data is available when a current and prior LesionQuant study have been processed and are available in the queue monitor. Change values of lesions are determined by using both 3D T1 and (2D or 3D) T2 FLAIR MRIs.

Morphometry Results
The change calculation of brain structures provides the difference between the current and prior scan brain volumes, percent of ICV, and normative percentile.

Cortechs.ai | Understanding Change Data in LesionQuant 2.3

Data from the prior study will also be included in the report for both lesions and brain volumes. Additionally, multi time-point-plotting displays the current and prior measurements on the same same report, allowing for ongoing patient evaluation with longitudinal tracking.

Lesion Results

  • Compare lesion count, volume and %ICV to prior scan
  • Review new and enlarging lesions, and the sum of the new and enlarging lesions
  • Evaluate where new and enlarging lesions are anatomically located, and examine the count of new lesions and the volume of new, enlarging and the sum of the new and enlarging lesions

Cortechs.ai | Understanding Change Data in LesionQuant 2.3

Cortechs.ai | Understanding Change Data in LesionQuant 2.3

 

Lesion Size Distribution Histogram
The histogram of lesion size distribution displays number of lesions within each lesion size bracket for current and prior scans. This data can characterize global lesion changes and provide an indication of disease progression.

Reproducibility and Comparison Best Practices
It is best practice to perform the current MRI on the same MRI scanner and series protocol as the prior MRI. If different scanners and/or protocols are used, caution should be taken when interpreting the results.

When patient data is already in the system
If an earlier scan for the patient has been processed by LesionQuant (same software version) and is available in the queue monitor, change volume images are automatically included in the output sent to the PACS/DICOM Viewer. The PatientID must match on both time points, and the StudyInstanceUID must match on the individual T1/FLAIR pair.

When patient data is no longer in the system or there has been a change in the software version from the prior scan
To obtain the change visualization, the user must reprocess the prior scan pair, then send the current scan pair for processing to receive the change analysis and volumes. The PatientID must match on both time points, and the StudyInstanceUID must match on the individual T1/FLAIR pair.

If the prior study is sent to LesionQuant for comparison reprocessing, it is important that the prior T1/FLAIR pair is processed completely before submitting the current T1/FLAIR pair.

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top